Trial Profile
Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Pravibismane (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors Microbion Corporation
- 15 Apr 2024 According to Microbion Corporation media release, the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.
- 27 May 2020 Status changed from active, no longer recruiting to completed, according to a Microbion Corporation media release.
- 09 Aug 2018 Planned End Date changed from 1 Jun 2018 to 31 Dec 2018.